Professor Sarfaraz K. Niazi Secures First-Ever FDA Acceptance to Waive Clinical Efficacy Studies for Monoclonal Antibody Biosimilars

Professor Sarfaraz K. Niazi Secures First-Ever FDA Acceptance to Waive Clinical Efficacy Studies for Monoclonal Antibody Biosimilars

CHICAGO, Sept. 1, 2025 /PRNewswire/ -- In a groundbreaking milestone for global healthcare and pharmaceutical innovation, Professor Sarfaraz K. Niazi, Adjunct Professor at the University of Illinois at Chicago and founder of multiple biopharmaceutical enterprises, has secured the first-ever FDA…

FDA to Waive Clinical Efficacy Studies for Monoclonal Antibody Biosimilars

This decision is believed to redefine how biological drugs will be developed, approved, and made affordable for patients.